MA27277A1 - Le pentafluorosulfanyl-benzoylguanidine, methode pour sa production et son utilisation comme medicament ou agent de diagnostique et medicament le contenant - Google Patents
Le pentafluorosulfanyl-benzoylguanidine, methode pour sa production et son utilisation comme medicament ou agent de diagnostique et medicament le contenantInfo
- Publication number
- MA27277A1 MA27277A1 MA27949A MA27949A MA27277A1 MA 27277 A1 MA27277 A1 MA 27277A1 MA 27949 A MA27949 A MA 27949A MA 27949 A MA27949 A MA 27949A MA 27277 A1 MA27277 A1 MA 27277A1
- Authority
- MA
- Morocco
- Prior art keywords
- drug
- benzoylguanidine
- pentafluorosulfanyl
- production
- same
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- GYZTWZKKXGLURP-UHFFFAOYSA-N FS(F)(F)(F)(F)N(C(=N)N)C(C1=CC=CC=C1)=O Chemical compound FS(F)(F)(F)(F)N(C(=N)N)C(C1=CC=CC=C1)=O GYZTWZKKXGLURP-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 2
- 229940039227 diagnostic agent Drugs 0.000 title 1
- 239000000032 diagnostic agent Substances 0.000 title 1
- 206010061216 Infarction Diseases 0.000 abstract 2
- 230000007574 infarction Effects 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000003293 cardioprotective effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000035778 pathophysiological process Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Pentafluorosulfanylbenzoylguanidines, procédé pour leur préparation, leur utilisation comme médicament ou aide diagnostique, et médicament les comportant Pentafluorosulfanylbenzoylguanidines de la formule I et II dans lequel R1 à R4 ont les significations énoncés dans les réclamations, convient en tant que médicaments anti-arythmiques avec un composant cardio-protecteur pour la prophylaxie de l'infarctus et le traitement de l'infarctus et pour le traitement des pectoris d'angine. Ils empêchent également préventivement les processus pathophysiologiques liés au développement des dommages ischémie-induits, particulièrement dans le déclenchement de ischémie induit des arythmies cardiaques.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10222192A DE10222192A1 (de) | 2002-05-18 | 2002-05-18 | Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27277A1 true MA27277A1 (fr) | 2005-04-01 |
Family
ID=29285565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA27949A MA27277A1 (fr) | 2002-05-18 | 2004-11-16 | Le pentafluorosulfanyl-benzoylguanidine, methode pour sa production et son utilisation comme medicament ou agent de diagnostique et medicament le contenant |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1509498B1 (fr) |
| JP (1) | JP4383341B2 (fr) |
| KR (1) | KR100977676B1 (fr) |
| CN (1) | CN100506791C (fr) |
| AR (1) | AR040034A1 (fr) |
| AT (1) | ATE343563T1 (fr) |
| AU (1) | AU2003242531B2 (fr) |
| BR (1) | BR0311128A (fr) |
| CA (1) | CA2486336C (fr) |
| CY (1) | CY1105867T1 (fr) |
| DE (2) | DE10222192A1 (fr) |
| DK (1) | DK1509498T3 (fr) |
| ES (1) | ES2274264T3 (fr) |
| HR (1) | HRP20041078B1 (fr) |
| IL (2) | IL165213A0 (fr) |
| MA (1) | MA27277A1 (fr) |
| ME (1) | MEP28908A (fr) |
| MX (1) | MXPA04011497A (fr) |
| MY (1) | MY139310A (fr) |
| NO (1) | NO333288B1 (fr) |
| PE (1) | PE20040452A1 (fr) |
| PL (1) | PL209700B1 (fr) |
| PT (1) | PT1509498E (fr) |
| RS (1) | RS50772B (fr) |
| RU (1) | RU2315752C2 (fr) |
| TW (1) | TWI281467B (fr) |
| WO (1) | WO2003097591A1 (fr) |
| ZA (1) | ZA200408886B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
| DE10338554A1 (de) * | 2003-08-22 | 2005-03-31 | Aventis Pharma Deutschland Gmbh | Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10353205A1 (de) * | 2003-11-13 | 2005-06-16 | Aventis Pharma Deutschland Gmbh | Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen |
| DE10353204A1 (de) * | 2003-11-13 | 2005-06-16 | Aventis Pharma Deutschland Gmbh | Verfahren zur Herstellung von 4-Pentafluorsulfanyl-benzoylguanidinen |
| OA13285A (en) * | 2003-11-13 | 2007-01-31 | Sanofi Aventis Deutschland | Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same. |
| DE102004043937A1 (de) * | 2004-09-11 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Synthese-Zwischenstufen |
| DE102004043938A1 (de) * | 2004-09-11 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| MX2009007482A (es) * | 2007-02-09 | 2009-08-13 | Pfizer Ltd | Agentes antiparasitarios. |
| CA2857831C (fr) * | 2007-03-23 | 2017-01-03 | Ube Industries, Ltd. | Procede de production de pentafluorures d'arylsoufre |
| JP5418226B2 (ja) * | 2007-08-28 | 2014-02-19 | 宇部興産株式会社 | ペンタフルオロスルファニルベンゼン化合物の製造方法、及び新規なペンタフルオロスルファニルベンゼン化合物 |
| RU2372331C1 (ru) * | 2008-05-14 | 2009-11-10 | Сергей Михайлович Игумнов | СПОСОБ ПОЛУЧЕНИЯ ДИ(C1-C6 алкил)АМИНОТРИФТОРСУЛЬФУРАНОВ |
| JP5439745B2 (ja) * | 2008-05-27 | 2014-03-12 | 宇部興産株式会社 | ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法 |
| EP2789603B1 (fr) * | 2011-12-06 | 2016-08-10 | Ube Industries, Ltd. | Procédé pour la production d'acide pentafluorosulfanylbenzoïque |
| CN108003034B (zh) * | 2017-12-26 | 2020-07-03 | 金凯(辽宁)化工有限公司 | 一种2-甲基-5-氨基三氟甲苯的制备方法 |
| RU2765117C2 (ru) * | 2019-09-24 | 2022-01-25 | Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" | Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4417004A1 (de) * | 1994-05-13 | 1995-11-16 | Hoechst Ag | Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19517848A1 (de) * | 1995-05-16 | 1996-11-21 | Merck Patent Gmbh | Fluorhaltige Benzoylguanidine |
| DE19526381A1 (de) * | 1995-07-19 | 1997-01-23 | Hoechst Ag | 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9606015D0 (en) * | 1996-03-22 | 1996-05-22 | Rhone Poulenc Agriculture | New herbicides |
-
2002
- 2002-05-18 DE DE10222192A patent/DE10222192A1/de not_active Withdrawn
-
2003
- 2003-04-25 PE PE2003000415A patent/PE20040452A1/es not_active Application Discontinuation
- 2003-05-05 DE DE50305498T patent/DE50305498D1/de not_active Expired - Lifetime
- 2003-05-05 JP JP2004505324A patent/JP4383341B2/ja not_active Expired - Fee Related
- 2003-05-05 AU AU2003242531A patent/AU2003242531B2/en not_active Ceased
- 2003-05-05 EP EP03752723A patent/EP1509498B1/fr not_active Expired - Lifetime
- 2003-05-05 CA CA2486336A patent/CA2486336C/fr not_active Expired - Fee Related
- 2003-05-05 MX MXPA04011497A patent/MXPA04011497A/es active IP Right Grant
- 2003-05-05 AT AT03752723T patent/ATE343563T1/de active
- 2003-05-05 DK DK03752723T patent/DK1509498T3/da active
- 2003-05-05 HR HRP20041078AA patent/HRP20041078B1/hr not_active IP Right Cessation
- 2003-05-05 BR BR0311128-8A patent/BR0311128A/pt not_active IP Right Cessation
- 2003-05-05 KR KR1020047018590A patent/KR100977676B1/ko not_active Expired - Fee Related
- 2003-05-05 ME MEP-289/08A patent/MEP28908A/xx unknown
- 2003-05-05 IL IL16521303A patent/IL165213A0/xx unknown
- 2003-05-05 WO PCT/EP2003/004669 patent/WO2003097591A1/fr not_active Ceased
- 2003-05-05 ES ES03752723T patent/ES2274264T3/es not_active Expired - Lifetime
- 2003-05-05 CN CNB038113198A patent/CN100506791C/zh not_active Expired - Fee Related
- 2003-05-05 PL PL371784A patent/PL209700B1/pl unknown
- 2003-05-05 RS YUP-990/04A patent/RS50772B/sr unknown
- 2003-05-05 RU RU2004137115/04A patent/RU2315752C2/ru not_active IP Right Cessation
- 2003-05-05 PT PT03752723T patent/PT1509498E/pt unknown
- 2003-05-15 TW TW092113151A patent/TWI281467B/zh not_active IP Right Cessation
- 2003-05-16 MY MYPI20031822A patent/MY139310A/en unknown
- 2003-05-16 AR ARP030101716A patent/AR040034A1/es active IP Right Grant
-
2004
- 2004-11-03 ZA ZA2004/08886A patent/ZA200408886B/en unknown
- 2004-11-15 IL IL165213A patent/IL165213A/en not_active IP Right Cessation
- 2004-11-16 MA MA27949A patent/MA27277A1/fr unknown
- 2004-12-14 NO NO20045447A patent/NO333288B1/no not_active IP Right Cessation
-
2006
- 2006-12-20 CY CY20061101825T patent/CY1105867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69629116T2 (de) | Isoxazoline und isoxazole als fibrinogen-rezeptor-antagonisten | |
| DE69534549T2 (de) | Kombination von retroviralen Proteasehemmern | |
| MA27347A1 (fr) | Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese | |
| MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
| MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
| US6046228A (en) | Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof | |
| BR0210838A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto | |
| EP2266621A3 (fr) | Compositions médicamenteuses à base de composés à action anticholinergiques et de betamimétiques | |
| MA27664A1 (fr) | Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese | |
| EP3585809B1 (fr) | Zafirlukast pour l'utilisation dans le traitement des thromboses | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
| BR9713921A (pt) | Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa | |
| WO2002094745A2 (fr) | Composes de liaison de cyclophiline non peptidique et leurs utilisations | |
| TNSN00250A1 (fr) | Composes nouveaux inhibiteurs de pcp, procede pour leur preparation et compositions les contenant | |
| RU2222538C2 (ru) | Оптически активное производное пиридил-4н-1,2,4-оксадиазина и фармацевтическая композиция | |
| BR0311128A (pt) | Pentafluorsulfanil-benzoilguanidinas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas | |
| WO2023150790A3 (fr) | Nouveaux inhibiteurs mpro du sars-cov-2 hautement sélectifs | |
| Feldman et al. | Pamaquine naphthoate as a prophylactic for malarial infections | |
| UA81610C2 (ru) | Изохинолиновые соединения, способ их получения и фармацевтическая композиция, которая их содержит | |
| DE102004034913A1 (de) | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren | |
| ATE408403T1 (de) | Deramciclan-enthaltende pharmazeutische zusammensetzung für die behandlung der verringerung kognitiver funktionen und/oder schäden davon | |
| Perlman | A study of the therapeutic action and toxicity of pentaerythritol tetranitrate | |
| EP0500586A1 (fr) | Inhibiteurs de biosynthese de pyrimidine utiles en tant qu'agents immunosuppresseurs | |
| MA27749A1 (fr) | 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-metoxy-pyridin-3-yl)-propyl]-benzamide, utilisation de ce compose sous la forme d'un medicament et preparations pharmaceutiques contenant ledit compose |